FY2026 Q3 Financial Results (Material)
Filed with TSE · · 47 pages · English
Summary by 6ix AI
The report highlights the company's advancements in manufacturing capabilities and the initiation of global clinical trials for its product Invimestrocel, aimed at treating acute respiratory distress syndrome. Additionally, it outlines the establishment of a commercial production system and plans for expansion into international markets, including the United States and Europe. The filing emphasizes Healios's commitment to scaling its operations and ensuring stable supply through innovative manufacturing processes.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Healios KK
- Shipment and Revenue Recognition of Initial Order of Culture Supernatant Products to JENECELL
- Notice Regarding Shipment Timing of Initial Order of Culture Supernatant Products to JENECELL
- FY2026 Q2 Financial Results (Material)
- Healios Selected for the AMED “Project to Promote the Industrialization of Regenerative/Cell Medicine and Gene Therapy”
- Notice Regarding the Filing of a Counterclaim in Response to a Lawsuit Filed Against Healios
Follow Healios KK into a list and get an email when it puts out news.
Follow Healios KK